• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Mcclurg Ronald W.

    5/16/22 7:08:22 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care
    Get the next $BTCY alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    McClurg Ronald W.

    (Last) (First) (Middle)
    275 SHORELINE DRIVE,
    SUITE 150

    (Street)
    REDWOOD CITY, CA 94065

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/04/2022
    3. Issuer Name and Ticker or Trading Symbol
    BIOTRICITY INC. [ BTCY ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Ronald McClurg 05/16/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BTCY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTCY

    DatePrice TargetRatingAnalyst
    11/20/2023Buy → Neutral
    H.C. Wainwright
    3/7/2022$5.00Buy
    Lake Street
    11/23/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BTCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

    REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e

    8/14/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th

    Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Sid

    8/12/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

    FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

    7/17/25 9:33:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    SEC Filings

    View All

    SEC Form 10-Q filed by Biotricity Inc.

    10-Q - BIOTRICITY INC. (0001630113) (Filer)

    8/14/25 7:01:14 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Biotricity Inc.

    10-K - BIOTRICITY INC. (0001630113) (Filer)

    7/15/25 5:27:01 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form NT 10-K filed by Biotricity Inc.

    NT 10-K - BIOTRICITY INC. (0001630113) (Filer)

    6/30/25 9:20:12 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rosa David A

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/15/23 4:22:52 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Al-Siddiq Waqaas

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/14/23 4:26:54 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Ayanoglou John

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/13/23 4:10:59 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

    SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

    11/14/24 6:06:28 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Biotricity Inc.

    SC 13G - BIOTRICITY INC. (0001630113) (Subject)

    8/8/24 6:09:48 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biotricity downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Biotricity from Buy to Neutral

    11/20/23 7:21:43 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Biotricity with a new price target

    Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00

    3/7/22 9:01:18 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. initiated coverage on Biotricity with a new price target

    HC Wainwright & Co. initiated coverage of Biotricity with a rating of Buy and set a new price target of $6.00

    11/23/21 6:29:32 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Financials

    Live finance-specific insights

    View All

    Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

    REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e

    8/14/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th

    Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Sid

    8/12/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

    FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

    7/17/25 9:33:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care